Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Abstract Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administration in Australia and may soon be publicly reimbursed. Th...
Main Authors: | Michael P Brown, Lisa M Ebert, Tessa Gargett |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Clinical & Translational Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1002/cti2.1050 |
Similar Items
-
Chimeric antigen receptor T-cells for glioblastoma: The journey ahead
by: Sujith Kurian Joseph, et al.
Published: (2019-01-01) -
Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
by: Craig A. Land, et al.
Published: (2020-11-01) -
Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
by: Long Li, et al.
Published: (2020-11-01) -
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
by: Elizabeth L. Siegler, et al.
Published: (2020-08-01) -
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
by: Hany E. Marei, et al.
Published: (2021-08-01)